InvestSMART

Alcidion Group Limited (ASX:ALC)

ALERT: Price-sensitive ASX Announcement for ALC
Current share price for ALC : $0.095 -0.005 (-5%)+
Announcement
Release
29 Apr 2026 8:22AM
Price at Release
$0.100
Full Release
download
Summary
Alcidion Group Limited reported a strong Q3 FY26 with revenue expected to exceed $50.0M and EBITDA over $5.0M. The company achieved a positive operating cashflow of $1.7M, bolstered by new sales of $11.7M, primarily driven by contract expansions in the UK and the first deployment of Miya Precision in Queensland. Alcidion maintained a cash balance of $15.1M with no debt as of March 31, 2026. The period saw strategic growth with significant contract expansions, including a 5-year agreement with Gold Coast Health for remote patient monitoring. The company is also on track to finalize a key EPR solution contract with UHSussex, expected to boost FY26 revenue. Alcidion continues to solidify its market presence in ANZ and the UK, enhancing its reputation as a preferred provider of healthcare technology solutions.
Key Points
  • Revenue expected to exceed $50.0M with EBITDA in excess of $5.0M.
  • Positive operating cashflow of $1.7M in Q3 FY26.
  • Cash balance of $15.1M and no debt as of March 31, 2026.
  • Q3 new TCV sales of $11.7M with significant contract expansions.
  • Continued growth in UK market with new contracts and renewals.
  • First deployment of Miya Precision in Queensland through Gold Coast Health.
  • Ongoing negotiations with UHSussex for new EPR solution.
  • Market presence strengthened across ANZ and UK.
  • Investor webcast scheduled for April 29, 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.